Insider Selling: Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) SVP Sells 8,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) SVP Iain Mcgill sold 8,000 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.42, for a total value of $1,067,360.00. Following the transaction, the senior vice president now directly owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded up $1.17 on Thursday, reaching $134.83. The company’s stock had a trading volume of 243,135 shares, compared to its average volume of 506,948. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. The stock has a market cap of $8,138.28, a P/E ratio of 17.03, a PEG ratio of 0.88 and a beta of 0.98. Jazz Pharmaceuticals PLC has a 12-month low of $99.53 and a 12-month high of $163.75.

Several research analysts have recently issued reports on the company. Deutsche Bank set a $175.00 price objective on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 9th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $192.00 price objective (up from $180.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 9th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, September 18th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $196.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $181.28.

Institutional investors and hedge funds have recently bought and sold shares of the business. AXA raised its stake in shares of Jazz Pharmaceuticals by 23.2% during the 3rd quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock worth $17,091,000 after buying an additional 22,007 shares in the last quarter. Neuberger Berman Group LLC raised its stake in shares of Jazz Pharmaceuticals by 26.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 117,345 shares of the specialty pharmaceutical company’s stock worth $17,162,000 after buying an additional 24,626 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of Jazz Pharmaceuticals by 4.8% during the 3rd quarter. California Public Employees Retirement System now owns 122,201 shares of the specialty pharmaceutical company’s stock worth $17,872,000 after buying an additional 5,601 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $291,000. Finally, Janney Montgomery Scott LLC raised its stake in shares of Jazz Pharmaceuticals by 29.4% during the 3rd quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock worth $257,000 after buying an additional 400 shares in the last quarter. 91.30% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) SVP Sells 8,000 Shares of Stock” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/07/jazz-pharmaceuticals-plc-jazz-svp-iain-mcgill-sells-8000-shares-of-stock.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply